Publication at First Faculty of Medicine |
2022
Abstract
Immunotherapy has become integrated into the standard treatment of patients with advanced NSCLC. There are available diffe-rent immunotherapy drugs, one of them is nivolumab.
Nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic NSCLC. Nivolumab as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC after prior chemotherapy in adults.
In both cases, nivolumab is for patients without EGFR mutation or ALK translocation. We present a clinical case of a 73 years old patient successfully treated with nivolumab as second-line therapy.
She received all 52 cycles of nivolumab monotherapy.